Startup Arcturus Therapeutics this week announced that it has acquired Marina Biotech’s unlocked nucleobase analog intellectual property in a move the company said would give it freedom to operate in the RNAi drugs space.

The transaction also represents Marina’s latest step toward monetizing its assets following a shutdown last summer. With this latest transaction, however, the company said it has gained much-needed breathing room as it tries to resume operations.